Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy

BJU International

Volumn 106, Issue 9, 2010, Pages 1266-1269

  Barbastefano, Juan ^a   Garcia, Jorge A ^a,b   Elson, Paul ^b   Wood, Laura S ^b   Lane, Brian R ^a   Dreicer, Robert ^a,b   Campbell, Steven C ^a   Rini, Brian I ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Fractional percentage of tumour volume; metastatic renal cell carcinoma and progression free survival

Indexed keywords

BEVACIZUMAB; HEMOGLOBIN; INTERLEUKIN 2; SORAFENIB; SUNITINIB; VASCULOTROPIN;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER GROWTH; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DATA BASE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEPHRECTOMY; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78349285605     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09323.x     Document Type: Article

References (17)

1. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171: 1071-6
2. Robertson CN, Linehan WM, Pass HI, et al. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol 1990; 6144
3. Fallick ML, McDermott DF, LaRock D, et al. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997; 158: 1691-5
4. Pierorazio PM, McKiernan JM, McCann TR, et al. Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional tumour Volume removed. BJU Int 2007; 100: 755-9
5. Chouri TK, Bukowski RM, Rini BI,. The current role of angiogenesis inhibitors in the treatment of renal cell-carcinoma. Semin Oncol 2006; 33: 596-606
6. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab an anti-vascular endothelial growth factor antibody for metastatic renal cell. N Engl J Med 2003; 349: 427-34
7. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-24
8. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal- cell carcinoma. N Engl J Med 2007; 356: 115-24
9. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34
10. Therasse P, Arbuck S, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000; 92: 205-16
11. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-96
12. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor targeted therapy. Cancer 2007; 110: 543-50
13. Dosquet C, Coudert MC, Lepage E, et al. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997; 3: 2451-8
14. Edgren M, Lennernas B, Larsson A, et al. Serum concentrations of VEGF and b-FGF in renal cell, prostate, and urinary bladder carcinoma. Anticancer Res 1999; 19: 869-73
15. Sato K, Tsuchiya N, Sasaki R, et al. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Cancer Res 1999; 90: 874-9
16. Jacobsen J, Rasmuson T, Grankvist K, et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000; 163: 343-7
17. Feldman AL, Alexander HR Jr, Yang JC, et al. Prospective analysisof circulating endostatin levels in patients with renal cell carcinoma. Cancer 2002; 95: 1637-43